Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.Pipeline progress included the approval ...

Shapiro failed to come through on a similar pledge to support transit during last year’s budget negotiations. The governor, ...